Does Andrew Huberman recommend Curcumin?
Andrew Huberman recommends Curcumin in some contexts, but has also raised cautions.
Published research rates it moderate evidence. Of Andrew Huberman's 67 tracked claims, 35 are supported or partially supported by studies on PubMed.
Evidence last reviewed May 2026
Andrew Huberman on Curcumin — 67 claims
“many of the early human trials with standard curcumin showed disappointing results despite promising in vitro and animal data.”
Early human trials with standard curcumin showed disappointing results despite promising in vitro and animal data.
None of the 10 provided studies contain extractable key findings, populations, or limitations data, making direct comparison impossible. The claim that early human trials with standard curcumin showed…
“When you see studies showing curcumin efficacy, check which formulation they used — most positive trials use enhanced formulations.”
Most positive curcumin trials use enhanced bioavailability formulations, not standard curcumin.
None of the 10 provided studies contain extractable key findings, populations, or limitations data that directly address whether positive curcumin trials preferentially use enhanced bioavailability fo…
“For inflammatory bowel disease, there's solid evidence supporting curcumin as an adjunct therapy.”
There is solid evidence supporting curcumin as an adjunct therapy for inflammatory bowel disease.
None of the 10 provided studies directly address curcumin as an adjunct therapy for inflammatory bowel disease (IBD). The retrieved literature covers osteoarthritis, healthy aging, exercise-induced mu…
“Plain curcumin powder has very poor oral bioavailability. It's poorly absorbed, rapidly metabolized, and quickly eliminated.”
Plain curcumin powder has very poor oral bioavailability — it is poorly absorbed, rapidly metabolized, and quickly eliminated.
None of the 10 provided studies contain extractable key findings, populations, or limitations data that directly address the pharmacokinetic properties of plain curcumin powder (absorption, metabolism…
“Phospholipid-bound curcumin (like Meriva or Phytosome formulations), nanoparticle curcumin, and lipid-based formulations also show dramatically improved absorption.”
Phospholipid-bound curcumin formulations (such as Meriva or Phytosome), nanoparticle curcumin, and lipid-based formulations show dramatically improved absorption compared to standard curcumin.
None of the 10 provided studies directly address the bioavailability or pharmacokinetic comparison between phospholipid-bound curcumin formulations (Meriva, Phytosome), nanoparticle curcumin, lipid-ba…
“curcumin combined with piperine — the active compound in black pepper — which increases bioavailability by roughly 2000 percent.”
Curcumin combined with piperine (the active compound in black pepper) increases bioavailability by roughly 2000 percent.
The specific claim that piperine increases curcumin bioavailability by ~2000% originates from a widely cited 1998 human study by Shoba et al. (not present in the provided literature list), and the cur…
“Plain curcumin powder has very poor oral bioavailability. It's poorly absorbed, rapidly metabolized, and quickly eliminated.”
Plain curcumin powder has very poor oral bioavailability — it is poorly absorbed, rapidly metabolized, and quickly eliminated.
None of the 10 provided studies contain extractable key findings specifically addressing the pharmacokinetic properties of plain curcumin (absorption, metabolism, elimination). While the claim about p…
“When you see studies showing curcumin efficacy, check which formulation they used — most positive trials use enhanced formulations.”
Most positive curcumin trials use enhanced bioavailability formulations, not standard curcumin.
The expert's claim that most positive curcumin trials use enhanced bioavailability formulations (e.g., piperine-combined, nanoparticle, or phospholipid complexes) is a methodological observation about…
“Phospholipid-bound curcumin (like Meriva or Phytosome formulations), nanoparticle curcumin, and lipid-based formulations also show dramatically improved absorption.”
Phospholipid-bound curcumin formulations (such as Meriva or Phytosome), nanoparticle curcumin, and lipid-based formulations show dramatically improved absorption compared to standard curcumin.
None of the 10 provided studies directly address the bioavailability of phospholipid-bound (e.g., Meriva/Phytosome), nanoparticle, or lipid-based curcumin formulations compared to standard curcumin. T…
“Multiple randomized controlled trials have shown that enhanced curcumin formulations reduce pain and improve function in knee osteoarthritis comparably to NSAIDs like ibuprofen in some studies, and with a better safety profile.”
Multiple randomized controlled trials have shown that enhanced curcumin formulations reduce pain and improve function in knee osteoarthritis comparably to NSAIDs like ibuprofen in some studies, and with a better safety profile.
Although the provided literature includes a meta-analysis (PMID: 34017975) and a GRADE-assessed systematic review and meta-analysis of RCTs on curcumin (PMID: 36804260) that could directly address thi…
“The typical dose in trials is 500 to 1000 milligrams of a bioavailability-enhanced formulation per day.”
The typical dose used in clinical trials is 500 to 1000 milligrams per day of a bioavailability-enhanced curcumin formulation.
While the provided research corpus includes several relevant systematic reviews and meta-analyses on curcumin supplementation (e.g., PMIDs 34017975, 36804260, 39203857), none of the retrieved records…
“curcumin combined with piperine — the active compound in black pepper — which increases bioavailability by roughly 2000 percent.”
Curcumin combined with piperine (the active compound in black pepper) increases bioavailability by roughly 2000 percent.
The specific claim of ~2000% bioavailability enhancement from curcumin-piperine co-administration originates from a well-known 1998 human pharmacokinetic study by Shoba et al. (not included in the pro…
“The typical dose in trials is 500 to 1000 milligrams of a bioavailability-enhanced formulation per day.”
The typical dose used in clinical trials is 500 to 1000 milligrams per day of a bioavailability-enhanced curcumin formulation.
While the retrieved literature includes multiple reviews and meta-analyses on curcumin (PMIDs 36804260, 29018060, 39203857, 35458170, among others), none of the provided records include extractable ke…
“Phospholipid-bound curcumin (like Meriva or Phytosome formulations), nanoparticle curcumin, and lipid-based formulations also show dramatically improved absorption.”
Phospholipid-bound curcumin formulations (such as Meriva or Phytosome), nanoparticle curcumin, and lipid-based formulations show dramatically improved absorption compared to standard curcumin.
None of the 10 provided studies directly address the comparative bioavailability of phospholipid-bound (e.g., Meriva/Phytosome), nanoparticle, or lipid-based curcumin formulations versus standard curc…
“For inflammatory bowel disease, there's solid evidence supporting curcumin as an adjunct therapy.”
There is solid evidence supporting curcumin as an adjunct therapy for inflammatory bowel disease.
None of the 10 provided studies directly examine curcumin as an adjunct therapy for inflammatory bowel disease (IBD). The retrieved literature covers curcumin's effects on osteoarthritis, metabolic he…
“Plain curcumin powder has very poor oral bioavailability. It's poorly absorbed, rapidly metabolized, and quickly eliminated.”
Plain curcumin powder has very poor oral bioavailability — it is poorly absorbed, rapidly metabolized, and quickly eliminated.
The claim that plain curcumin has poor oral bioavailability — being poorly absorbed, rapidly metabolized, and quickly eliminated — is a well-established pharmacokinetic fact documented extensively in…
“many of the early human trials with standard curcumin showed disappointing results despite promising in vitro and animal data.”
Early human trials with standard curcumin showed disappointing results despite promising in vitro and animal data.
The expert's claim that early human trials with standard curcumin showed disappointing results due to poor bioavailability is a commonly cited narrative in the curcumin literature, but none of the pro…
“Multiple randomized controlled trials have shown that enhanced curcumin formulations reduce pain and improve function in knee osteoarthritis comparably to NSAIDs like ibuprofen in some studies, and with a better safety profile.”
Multiple randomized controlled trials have shown that enhanced curcumin formulations reduce pain and improve function in knee osteoarthritis comparably to NSAIDs like ibuprofen in some studies, and with a better safety profile.
The retrieved literature includes relevant meta-analyses and systematic reviews (PMIDs 29018060, 35458170, 36804260) that broadly address curcumin/turmeric supplementation and osteoarthritis outcomes,…
“curcumin combined with piperine — the active compound in black pepper — which increases bioavailability by roughly 2000 percent.”
Curcumin combined with piperine (the active compound in black pepper) increases bioavailability by roughly 2000 percent.
The specific claim of ~2000% bioavailability enhancement from curcumin-piperine co-supplementation originates from a well-known 1998 human pharmacokinetic study (Shoba et al.) that is not directly lis…
“Multiple randomized controlled trials have shown that enhanced curcumin formulations reduce pain and improve function in knee osteoarthritis comparably to NSAIDs like ibuprofen in some studies, and with a better safety profile.”
Multiple randomized controlled trials have shown that enhanced curcumin formulations reduce pain and improve function in knee osteoarthritis comparably to NSAIDs like ibuprofen in some studies, and with a better safety profile.
While the provided literature includes a meta-analysis (PMID: 34017975) and a GRADE-assessed systematic review (PMID: 36804260) that are relevant study types to evaluate the expert's claim, none of th…
Other supplements Andrew Huberman discusses
Claims are extracted from publicly available podcasts and videos, attributed to their source, and compared against PubMed research. This is educational information only — consult a healthcare provider before starting any supplement.
Back to Andrew Huberman